The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials
Crossref DOI link: https://doi.org/10.1186/s12882-016-0357-9
Published Online: 2016-09-30
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schulman, Gerald
Berl, Tomas
Beck, Gerald J.
Remuzzi, Giuseppe
Ritz, Eberhard
Shimizu, Miho
Shobu, Yuko
Kikuchi, Mami
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation
Kureha Corporation
License valid from 2016-09-30